Improved reporting for adverse drug reactions

  • Date: 12 February 2020

REPORTING adverse drug reactions via the Yellow Card Scheme has been made easier thanks to a technology update.

GP practice teams in England can now use EMIS Web to submit reports to the Medicines and Healthcare products Regulatory Agency (MHRA).

Around 4,000 practices will now be able to take advantage of integrated reporting. The facility is already in place for those using SystmOne and Vision.

This latest update takes the proportion of UK GP practices with access to integrated reporting to 93 per cent.

Yellow Card reports act as an early warning of previously unrecognised adverse drug reactions (ADRs) as well as providing information on those already known.

MHRA said: "Integrated Yellow Card reporting ensures patient details are anonymised and provides an easier, faster and more secure method for healthcare professionals to report suspected ADRs through a few simple steps.

"Much of the information needed is automatically populated from the patient and reporter record. This mean that reporters only need to complete a few additional pieces of information. A copy of the report is also held on the patient’s record."

Mick Foy from MHRA said: "All Yellow Card reports can be a source of potential new safety information. Expanding the availability of easy-to-use routes of reporting is invaluable towards increased reporting and protecting patient safety."

Reporting guidance for EMIS Web users is available on EMIS Now 

This page was correct at the time of publication. Any guidance is intended as general guidance for members only. If you are a member and need specific advice relating to your own circumstances, please contact one of our advisers.

Save this article

Save this article to a list of favourite articles which members can access in their account.

Save to library

Related Content

Coroner's inquests

Roundtable part 2 - Diagnosing conditions with a slower progression

Roundtable part 1 - Dealing with serious childhood illnesses

For registration, or any login issues, please visit our login page.